Neurological
|
February 7, 2025

How Atogepant Can Transform Your Migraine Management Journey

Written By
Medically Reviewed by
Updated On
February 12, 2025

If you've ever had a migraine, you know how painful it can be. The pounding headache, feeling sick, and trouble with bright lights can make it hard to do anything. 

Migraines don't just hurt; they can stop you from working, spending time with family, or even doing simple things like cooking or reading.

Thankfully, new treatments are available to help reduce the frequency of migraines in some individuals. One of these is atogepant, a medicine that can lower how often you get migraines and improve the quality of life for some patients. 

This article will explain what atogepant is, how it works, its benefits, possible side effects, and how it compares to other migraine treatments.

[signup]

Understanding Atogepant

Atogepant is a medication designed to help prevent migraines. It belongs to a class of drugs called CGRP inhibitors (calcitonin gene-related peptide inhibitors). CGRP is a protein in the body that plays a role in migraine attacks. 

When CGRP levels are high, blood vessels in the brain widen, leading to inflammation and pain. Atogepant works by blocking CGRP, which has been shown in clinical studies to reduce migraine frequency in some individuals.

The U.S. Food and Drug Administration (FDA) has approved atogepant as a preventive treatment for migraines in adults. This means it is used to reduce the frequency of migraines rather than treat them once they start. 

Unlike some migraine medications that require injections, atogepant comes in a pill form, offering an oral alternative to injectable migraine prevention treatments.

How Atogepant Works

Atogepant stops CGRP from attaching to its receptors in the brain. Think of CGRP as a "key" that unlocks migraine symptoms. Atogepant acts like a "block" that prevents the key from fitting into the lock, interfering with the biological pathways involved in migraine development. 

By blocking CGRP, atogepant helps lower inflammation and reduce the widening of blood vessels, stopping the trigger of migraines.

Studies suggest that atogepant can significantly reduce the number of migraine days per month for people who experience frequent migraines. It may also lower the severity of migraines when they do occur. 

Because it is taken daily, atogepant provides continuous protection, helping people go about their lives with fewer interruptions from migraines.

Benefits and Efficacy of Atogepant

Atogepant has been shown to help many people experience fewer migraines, with studies supporting its effectiveness and advantages over older treatments.

Clinical Efficacy

Several clinical trials have tested atogepant for migraine prevention. 

One major study, a double-blind trial published in The New England Journal of Medicine, found that atogepant was effective in reducing the number of migraine and headache days over a 12-week period. 

Advantages Over Traditional Treatments

Compared to older migraine prevention medications, such as beta-blockers, anticonvulsants, and tricyclic antidepressants, atogepant offers several advantages. 

Traditional treatments often come with side effects like fatigue, weight gain, or brain fog, which can be challenging for patients to manage. Atogepant, as a CGRP antagonist, works differently and tends to have a more favorable side effect profile.

One key benefit is improved patient compliance. Many traditional medications require daily dosing and come with potential interactions with other drugs. Atogepant, available in a convenient oral tablet, is designed for once-daily use, making it easier for patients to incorporate into their routine. 

This ease of use and its effectiveness may help individuals stick to their migraine management plan with greater success.

By offering a targeted approach with a distinct side effect profile that some patients may better tolerate, atogepant represents a significant step forward in migraine prevention.

Usage and Dosage Guidelines

Understanding how to take atogepant correctly can help you get the most benefit from this migraine prevention medication.

Who Can Use Atogepant?

Atogepant is approved for adults who experience both chronic and episodic migraines. 

Chronic migraine sufferers have headaches 15 or more days per month, while those with episodic migraines experience them less frequently. If you struggle with frequent migraines, talk to your doctor about whether atogepant is right for you.

This medication may not be suitable for everyone. People with certain medical conditions or those taking specific medications should consult their healthcare provider before starting atogepant. 

Pregnant or breastfeeding individuals should also discuss the risks and benefits with their doctor.

Dosage and Administration

Atogepant is typically taken once a day as a tablet. The exact dose will depend on your doctor's recommendation, but typical doses include 10 mg, 30 mg, or 60 mg per day. It can be taken with or without food, making it easy to fit into your routine.

To get the best results, take atogepant at the same time each day. Setting a reminder on your phone or linking it to another daily habit—like brushing your teeth—can help you stay consistent. If you ever miss a dose, follow your doctor's advice on how to proceed.

By following these guidelines, atogepant can become a simple and effective part of your migraine management plan.

Side Effects and Safety Profile

Like any medication, atogepant may cause side effects, but understanding them can help you feel more confident about your treatment plan.

Common Side Effects

Common side effects include:

Long-Term Safety

Studies show that atogepant is generally safe for long-term use. Clinical trials lasting over a year have monitored patients for serious side effects, and the results suggest that most people tolerate the medication well. 

Long-term studies have not identified significant safety concerns, but ongoing monitoring continues to assess its safety profile.

Talk to your doctor if you have concerns about side effects or long-term safety. They can help you decide if atogepant is a good fit for your migraine management plan.

Navigating Access and Cost

Understanding how to access and afford atogepant can help you incorporate this medication into your migraine prevention plan.

Insurance and Prescription Coverage

Atogepant, marketed as QULIPTA® in the U.S., is covered by many commercial insurance plans. For eligible patients with commercial insurance, the QULIPTA Complete Savings Program offers assistance in reducing out-of-pocket costs. 

Patients can enroll online to access a savings card, which may allow them to pay as little as $0 per month, depending on their insurance coverage.

For those without insurance or limited coverage, AbbVie's myAbbVie Assist program provides atogepant at no cost to qualifying patients. This program is intended for individuals in the United States who meet specific financial criteria.

Organizations like the National Headache Foundation also list various patient assistance programs that may offer support for migraine medications, including atogepant.

Global Availability

Atogepant is approved for migraine prevention in multiple countries. In the United States, it is available under the brand name QULIPTA®. 

In the European Union, it is marketed as AQUIPTA® and has been approved for the prevention of migraine in adults experiencing at least four migraine days per month.

As of now, atogepant is approved in 45 countries worldwide. AbbVie continues to pursue additional regulatory approvals to make atogepant accessible to more patients globally.

If you're considering atogepant for migraine prevention, consult your healthcare provider to determine if it's the right option for you and to understand the access and support programs available in your region.

[signup]

Key Takeaways

  • Atogepant is an FDA-approved oral medication that prevents migraines by blocking CGRP, which has been shown in clinical studies to reduce migraine frequency and severity.
  • Clinical studies show it significantly lowers migraine days per month with fewer side effects than traditional treatments.
  • Its once-daily pill form makes it a convenient and well-tolerated option for long-term migraine prevention.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

No lab tests!

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine. (2024). AbbVie News Center. https://news.abbvie.com/2024-04-12-AbbVie-Announces-Late-Breaking-Data-at-AAN-Supporting-Long-Term-Safety-and-Efficacy-of-Atogepant-QULIPTA-R-for-Preventive-Treatment-of-Migraine

Ailani, J., Lipton, R. B., Goadsby, P. J., Guo, H., Miceli, R., Severt, L., Finnegan, M., & Trugman, J. M. (2021). Atogepant for the Preventive Treatment of Migraine. New England Journal of Medicine, 385(8), 695–706. https://doi.org/10.1056/nejmoa2035908

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. (n.d.). https://ec.europa.eu/health/documents/community-register/2023/20230811159911/anx_159911_en.pdf

Ashina, M., Tepper, S. J., Reuter, U., Blumenfeld, A. M., Hutchinson, S., Xia, J., Miceli, R., Severt, L., Finnegan, M., & Trugman, J. M. (2023). Once‐daily oral atogepant for the long‐term preventive treatment of migraine: Findings from a multicenter, randomized, open‐label, phase 3 trial. Headache: The Journal of Head and Face Pain, 63(1), 79–88. https://doi.org/10.1111/head.14439

Atogepant (oral route). (2024). Mayo Clinic. https://www.mayoclinic.org/drugs-supplements/atogepant-oral-route/description/drg-20523241

Atogepant: MedlinePlus Drug Information. (n.d.). Medlineplus.gov. https://medlineplus.gov/druginfo/meds/a621052.html

Brooks, M. (2023, April 28). FDA Expands Atogepant Approval to Include Chronic Migraine. Medscape. https://www.medscape.com/viewarticle/991371

Bryant, A. (2024, October 25). Lab Tests for Patients with Dry Mouth and Eyes. Rupa Health. https://www.rupahealth.com/post/lab-tests-for-patients-with-dry-mouth-and-eyes

Cloyd, J. (2023a, March 7). An integrative medicine approach to fatigue. Rupa Health. https://www.rupahealth.com/post/an-integrative-medicine-approach-to-fatigue

Cloyd, J. (2023b, May 17). A Functional Medicine Constipation Protocol: Testing, Nutrition, and Supplements. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-constipation-protocol-testing-nutrition-and-supplements

Cloyd, J. (2023c, August 25). A Root Cause Medicine Protocol For Patients With Insomnia: Testing, Therapeutic Diet, and Supportive Supplements. Rupa Health. https://www.rupahealth.com/post/a-root-cause-medicine-protocol-for-patients-with-insomnia-testing-therapeutic-diet-and-supportive-supplements

Danesh, A., & Gottschalk, P. C. H. (2019). Beta-Blockers for Migraine Prevention: a Review Article. Current Treatment Options in Neurology, 21(4). https://doi.org/10.1007/s11940-019-0556-3

Dosing and Administration | QULIPTATM (atogepant) HCP. (n.d.). Www.quliptahcp.com. https://www.quliptahcp.com/dosing

Henry, E. (2022, February 4). Studies Show These 2 Diets Reduce Migraine Severity And Frequency. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-approach-to-migraines

HIGHLIGHTS OF PRESCRIBING INFORMATION. (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215206s004lbl.pdf

Jackson, J. L., Shimeall, W., Sessums, L., DeZee, K. J., Becher, D., Diemer, M., Berbano, E., & O’Malley, P. G. (2010). Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ, 341(oct20 1), c5222–c5222. https://doi.org/10.1136/bmj.c5222

Lew, C., & Punnapuzha, S. (2023, May 1). Migraine Medications. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK553159/

Meglio, M. (2023, August 20). CGRP Medication Atogepant Gains European Commission Approval as Migraine Preventive. Neurology Live. https://www.neurologylive.com/view/cgrp-medication-atogepant-european-commission-approval-migraine-preventive

Mohanty, D., & Lippmann, S. (2020). CGRP Inhibitors for Migraine. Innovations in Clinical Neuroscience, 17(4-6), 39. https://pmc.ncbi.nlm.nih.gov/articles/PMC7413335/

Mulleners, W., & Chronicle, E. (2008). Anticonvulsants in Migraine Prophylaxis: A Cochrane Review. Cephalalgia, 28(6), 585–597. https://doi.org/10.1111/j.1468-2982.2008.01571.x

Patient Assistance Programs | National Headache Foundation. (n.d.). Https://Headaches.org/. https://headaches.org/resources/patient-assistance-programs/

Pescador Ruschel, M. A., & De Jesus, O. (2024, July 5). Migraine headache. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK560787/

Pozo-Rosich, P., Ailani, J., Ashina, M., Goadsby, P. J., Lipton, R. B., Reuter, U., Guo, H., Schwefel, B., Lu, K., Boinpally, R., Miceli, R., De Abreu Ferreira, R., McCusker, E., Yu, S. Y., Severt, L., Finnegan, M., & Trugman, J. M. (2023). Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 402(10404), 775–785. https://doi.org/10.1016/S0140-6736(23)01049-8

QULIPTATM (atogepant) Cost. (n.d.). Www.qulipta.com. https://www.qulipta.com/cost

Ramesh Boinpally, Mohamad Shebley, & Trugman, J. M. (2024). Atogepant: Mechanism of action, clinical and translational science. Clinical and Translational Science, 17(1). https://doi.org/10.1111/cts.13707

Rissardo, J. P., & Caprara, A. L. F. (2022). Gepants for Acute and Preventive Migraine Treatment: A Narrative Review. Brain Sciences, 12(12), 1612. https://doi.org/10.3390/brainsci12121612

Rizzoli, P., Marmura, M. J., Robblee, J., McVige, J., Sacco, S., Nahas, S. J., Ailani, J., De, R., Ma, J., Smith, J. H., Dabruzzo, B., & Messoud Ashina. (2024). Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials. The Journal of Headache and Pain, 25(1). https://doi.org/10.1186/s10194-024-01736-z

Sign Up - QULIPTA® (atogepant) Complete Savings Program. (2024). Qulipta.com. https://www.qulipta.com/savings-support/qulipta-complete-savings-program

Wattiez, A.-S., Sowers, L. P., & Russo, A. F. (2020). Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert Opinion on Therapeutic Targets, 24(2), 91–100. https://doi.org/10.1080/14728222.2020.1724285

Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Neurological
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.

Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.